Category: Technology Licenses
Created On: 2022-04-28
Record Count: 6
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 28662
The Technology is regarding a molecular and cellular approach directed at converting liver cells into functional insulin producing cells, as a treatment for diabetes.
Granted Patents 6,774,120
IPSCIO Record ID: 4422
The Licensee was granted a worldwide, exclusive license to certain information regarding a molecular and cellular approach directed at converting liver cells into functional insulin producing cells, as treatment for diabetes.
IPSCIO Record ID: 27800
One area of use is to increase the number of stem cells available to convert into pancreatic islet cells, thereby increasing the number of islet cells that can be impl. Producing new islet cells has proven to be a difficult task. Differentiating pluripotent stem cells into islet cells has been accomplished in the laboratory and is still hoped to be the answer for treating or possibly curing type 1 diabetes.
This treatment for type 1 diabetes would be to transplant insulin-producing islet cells into the body. The Edmonton Protocol is a method of implanting pancreatic islets into the liver for the treatment of type 1 diabetes.
IPSCIO Record ID: 28403
09/736,268 Transfer to De-Differentiate Recipient Cells
IPSCIO Record ID: 28404
By way of example, but not in limitation, Licensee shall have the right to use Licensed Technology within the Field for the following purposes to produce mammalian embryonic stem (ES) cells and to produce from those mammalian embryonic cells, differentiated cells for human therapeutic purposes or for commercial research purposes, including drug screening assays, and to produce pluripotent cells including ES cells, differentiated human cells for human diagnostic and therapeutic purposes and/or for commercial research purposes, including drug screening assays. b) A royalty bearing, twelve (12) month exclusive license in the Territory in the Field to expand in culture, prepare for sale, sell, offer for sale, import and export Act Animal Cell Lines. The twelve-month term of exclusivity granted to Licensee shall begin upon the date of the first sale of the Act Animal Cell Lines. Licensor and Licensee agree that after the twelve-month period of exclusivity has passed, Licensor and Licensee shall negotiate in good faith to establish reasonable minimum sales goals over reasonable evaluation periods in order to maintain Licenseeâ€™s exclusive rights hereunder. If Licensor fails to meet the minimum sales goals then Licenseeâ€™s exclusive rights shall revert to nonexclusive rights.
08/935,052 US 1997-09-22 CICM Cells and Non-Human Mammalian Embryos
6,235,970 2001-05-22 Prepared by Nuclear Transfer of a Proliferating Differentiated Cell or its Nucleus
09/828,876 US 2001-04-10 Cloning Using Donor Nuclei from Differentiated Fetal and Adult Cells UMASS
10/374,512 US 2003-02-27 Gynogenetic or Androgenetic Production of Pluripotent Cells and Cell Lines, and Use Thereof to Produce Differentiated Cells and Tissues
60/161,987 US 1999-10-28 Gynogenetic or Androgenetic Production of Pluripotent Cells and Cell Lines, and Use Thereof to Produce Differentiated Cells and Tissues
2,387,506 CA 2000-10-27 Gynogenetic or Androgenetic Production of Pluripotent Cells and Cell Lines, and Use Thereof to Produce Differentiated Cells and Tissues
Declared patent interferences
a) Patent Interference No. 104,746, involving U.S. Patent No. 5,945,577 and U.S. Patent Application No. 09/650,194.
b) Patent Interference No. 105,192, involving U.S. Patent No. 6,235,970 and U.S. Patent Application No. 09/989,126.
Potential patent interferences, verbally threatened to be filed against the following patents
IPSCIO Record ID: 26263
5,453,366 Method of Cloning Bovine Embryos
6,011,197 Method of Cloning Bovines Using Reprogrammed Non-mbryonic Bovine Cells
6,258,998 Method of Cloning Porcine Animals
5,843,754 Parthenogenic Bovine Oocyte Activation
5,496,720 Parthenogenic Oocyte Activation
09/573,044 Use of embryonic stem cells as nuclear donors during nuclear transfer and use of said techniques to produce chimeric and transgenic animals.
6,194,202 Parthenogenic Oocyte Activation
6,077,710 Parthenogenic Oocyte Activation
6,107,543 Culture of Totipotent Embryonic Inner Cells Mass Cells and Production of Bovine